GSK Nabs $40M Arbitral Award In Migraine Drug Row
A tribunal has awarded GlaxoSmithKline PLC nearly $40 million in its arbitration over claims related to a deal for U.S. rights to the drugmaker's Treximet prescription migraine treatment with New Jersey-based...To view the full article, register now.
Already a subscriber? Click here to view full article